Randomized clinical trial
Randomized clinical trial comparing standard diet with perioperative oral immunonutrition in total gastrectomy for gastric cancer. BJS 2017; 104: n/a-n/a.
Authors: S. Ida, N. Hiki, H. Cho, K. Sakamaki, S. Ito, K. Fujitani et al.
Notes: Immunonutrition of no benefit
Systemic inflammatory markers and outcome in patients with locally advanced adenocarcinoma of the oesophagus and gastro‐oesophageal junction. BJS 2017; 104: 401-407.
Authors: V. P. Jagadesham, S. M. Lagarde, A. Immanuel, S. M. Griffin
Notes: Could help in treatment stratification
Gastrointestinal symptoms and food intolerance 2 years after laparoscopic Roux‐en‐Y gastric bypass for morbid obesity. BJS 2017; 104: 393-400.
Authors: T. C. C. Boerlage, A. W. J. M. van de Laar, S. Westerlaken, V. E. A. Gerdes, D. P. M. Brandjes
Notes: High prevalence of food intolerance
Patterns of recurrence after oesophagectomy and postoperative chemoradiotherapy versus surgery alone for oesophageal squamous cell carcinoma. BJS 2017; 104: 90-97.
Authors: P.‐K. Hsu, H.‐S. Chen, C.‐S. Huang, C.‐C. Liu, C.‐C. Hsieh, H.‐S. Hsu et al.
Notes: Longer survival and less recurrence with multimodal treatment
Cost‐effectiveness of emergency versus delayed laparoscopic cholecystectomy for acute gallbladder pathology. BJS 2017; 104: 98-107.
Authors: A. J. Sutton, R. S. Vohra, M. Hollyman, P. J. Marriott, A. Buja, D. Alderson et al.
Notes: Emergency cholecystectomy is cheaper and more effective
Population‐based cohort study of variation in the use of emergency cholecystectomy for benign gallbladder diseases. BJS 2016; 103: 1716-1726.
Authors: R. S. Vohra, S. Pasquali, A. J. Kirkham, P. Marriott, M. Johnstone, P. Spreadborough et al.
Notes: Similar patients, not similar care
Early outcomes from the Dutch Upper Gastrointestinal Cancer Audit. BJS 2016; 103: 1855-1863.
Authors: L. A. D. Busweiler, B. P. L. Wijnhoven, M. I. van Berge Henegouwen, D. Henneman, N. C. T. van Grieken, M. W. J. M. Wouters et al.
Notes: High‐quality national audit when properly resourced
Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro‐oesophageal junction based on a national data registry. BJS 2016; 103: 1864-1873.
Authors: F. Klevebro, M. Lindblad, J. Johansson, L. Lundell, M. Nilsson
Notes: Real‐world survival less impressive than RCTs